Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0EWQKX
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Ozuriftamab vedotin
|
|||||
| Synonyms |
BA3021; Ba-3021; CAB Ror2-ADC; CAB-ADC; CAB-ROR2; CAB-ROR2-ADC; HTBA3021; Ozuriftamab vedotin
Click to Show/Hide
|
|||||
| Organization |
BioAtla, Inc.; Kaibos (Shanghai) Biomedical Co., Ltd.
|
|||||
| Drug Status |
Phase 2
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Ozuriftamab
|
Antibody Info | ||||
| Antigen Name |
Tyrosine-protein kinase transmembrane receptor ROR2 (ROR2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
vedotin
|
|||||
| Puchem SID | ||||||
| Drugbank ID | ||||||
| ChEBI ID | ||||||
